<SEC-DOCUMENT>0000950170-24-037525.txt : 20240327
<SEC-HEADER>0000950170-24-037525.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240327211020
ACCESSION NUMBER:		0000950170-24-037525
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240327

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvalent, Inc.
		CENTRAL INDEX KEY:			0001861560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-40671
		FILM NUMBER:		24793123

	BUSINESS ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		508-446-2272

	MAIL ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BCLS II Investco, LP
		CENTRAL INDEX KEY:			0001818893
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6175162878

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001818893</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001861560</issuerCik>
<issuerName>Nuvalent, Inc.</issuerName>
<secFileNumber>001-40671</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">One Broadway</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">14th Floor</street2>
<city xmlns="http://www.sec.gov/edgar/common">Cambridge</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02142</zipCode>
</issuerAddress>
<issuerContactPhone>857-357-7000</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>BCLS II INVESTCO, LP</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Affiliate</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Goldman Sachs &amp; Co. LLC</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">200 West Street</street1>
<city xmlns="http://www.sec.gov/edgar/common">New York</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10282</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>880000</noOfUnitsSold>
<aggregateMarketValue>66651200</aggregateMarketValue>
<noOfUnitsOutstanding>58632384</noOfUnitsOutstanding>
<approxSaleDate>03/27/2024</approxSaleDate>
<securitiesExchangeName>Nasdaq</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
<acquiredDate>08/02/2021</acquiredDate>
<natureOfAcquisitionTransaction>Purchase of Common Stock in an underwritten public offering</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Underwriter</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>731465</amountOfSecuritiesAcquired>
<paymentDate>08/02/2021</paymentDate>
<natureOfPayment>Cash</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
<acquiredDate>11/03/2022</acquiredDate>
<natureOfAcquisitionTransaction>Purchase of Common Stock in an underwritten public offering</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Underwriter</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>148535</amountOfSecuritiesAcquired>
<paymentDate>11/03/2022</paymentDate>
<natureOfPayment>Cash</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<noticeSignature>
<noticeDate>03/27/2024</noticeDate>
<signature>/s/ Andrew Hack, as Partner of Bain Capital Life Sciences Investors, LLC</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
